Last reviewed · How we verify

Recarbrio — Competitive Intelligence Brief

Recarbrio (RELEBACTAM) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Renal Dehydropeptidase Inhibitor [EPC]. Area: Infectious Disease.

marketed Renal Dehydropeptidase Inhibitor [EPC] Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Recarbrio (RELEBACTAM) — Merck & Co.. Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Recarbrio TARGET RELEBACTAM Merck & Co. marketed Renal Dehydropeptidase Inhibitor [EPC] 2019-01-01
IMIPENEM ANHYDROUS IMIPENEM ANHYDROUS marketed Renal Dehydropeptidase Inhibitor [EPC] 1985-01-01
Primaxin CILASTATIN Merck & Co. marketed Renal Dehydropeptidase Inhibitor Dipeptidase 1 1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Renal Dehydropeptidase Inhibitor [EPC] class)

  1. · 1 drug in this class
  2. Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recarbrio — Competitive Intelligence Brief. https://druglandscape.com/ci/relebactam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: